The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Ludwig Cancer Research congratulates Douglas Hanahan, Ludwig Distinguished Scholar at the Lausanne Branch of the Ludwig Institute for Cancer Research, on his election as Foreign Member of the Royal Society.
An international study led by MELIS-UPF researchers from the Infection Biology and Molecular Virology laboratories has identified and characterized Schlafen 12 (SLFN 12) as a novel HIV restriction factor.
Experts from Indiana University are available to comment on trending topics for the week of May 8, including the Writer's Guild of America strike, the ongoing investigation into the leak of classified military documents on Discord, and the role of climate change in an early allergy season.
Rutgers team that created the new COVID vaccine aims to partner with a pharmaceutical company to launch human trials.
The immune system has a biological telecommunications system — small proteins known as interleukins that send signals among the leukocyte white blood cells to control their defense against infections or nascent cancer.
At the 184th ASA Meeting, Ashley Alva of the Georgia Institute of Technology will describe how attaching microbubbles to macrophages, a type of white blood cell, can create high-resolution and sensitive tracking images useful for disease diagnosis. Because of the attached microbubbles, the cells sent back an echo when hit with ultrasound, which is nonionizing and noninvasive and has great depth of penetration. This allowed the team to visualize the macrophages in vivo with high resolution and sensitivity. Visualizing macrophages in vivo could also provide a powerful tool for understanding immune responses and monitoring therapeutic efficacy.
A recent clinical trial showed that the drug combination of cemiplimab plus platinum chemotherapy can prolong survival in patients with advanced lung cancer when compared with placebo plus platinum chemotherapy. Now an analysis published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society, indicates that cemiplimab plus platinum chemotherapy also affects quality of life compared to chemotherapy alone.
UC San Diego scientists find an auto-signaling mechanism driving the T cell anti-tumor response; findings may inspire new cancer therapeutics and biomarkers.
Findings reveal a previously unknown way in which the brain and immune system talk to each other and may identify a new therapeutic target for MS and other brain disorders.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right